Samsung Biologics, a global contract development and manufacturing organization (CDMO) and Kurma Partners, a European venture capital firm in healthcare and biotechnology, announced a strategic partnership for the development and manufacturing of biologics for Kurma Partners’ portfolio companies.
Under the terms of the multi year agreement, Samsung Biologics will provide customizable chemistry, manufacturing, and control (CMC) development services for Kurma Partners’ portfolio companies to streamline the gene to Investigational New Drug ( IND process , de risk uncertainties in CMC, and accelerate the lead candidate selection through entry into first in human studies with seamless transitions along further clinical development The portfolio companies will be able to leverage Samsung Biologics’ state of the art facilities, proprietary technology platforms, and CMC related expertise.
“As we look to further expand our business opportunities globally, we are pleased to collaborate with Kurma Partners to support the growth of pioneering biotech companies,” said John Rim, president and CEO of Samsung Biologics. “With our in depth knowledge on effective scale up strategy and a diverse portfolio of proprietary platform technologies, we are looking forward to providing robust CMC solutions to reduce uncertainties, ensure regulatory compliance, and ultimately maximize manufacturing efficiency for our clients.”
“We are very excited to partner with Samsung Biologics, a world leading CDMO with capabilities of highest industry standards. This will greatly benefit our portfolio of Kurma Biofunds and Kurma Growth Opportunities Fund in advancing large molecule biologic s from discovery to the market. market.” said Daniel Parera, M.D., Partner at Kurma Partners.
The latest agreement reflects Samsung Biologics’ continued commitment to support emerging biotech companies on their drug development and manufacturing journey as well as further increase its business presence in major sectors with a focus on the US and European markets.
Samsung Biologics is a fully integrated, end-to-end CDMO service provider, offering seamless development and manufacturing solutions from cell line development to final aseptic fill/finish as well as laboratory testing support for the biopharmaceutical products we manufacture.
Founded in July 2009 and based in Paris and Munich, Kurma Partners is a key European Venture Capital firm in the financing of innovation in Healthcare and Biotechnology, from pre-seed to growth capital, in particular through its funds Kurma Biofund I, II, III, Kurma Diagnostics and Kurma Diagnostics 2 and its recent Kurma Growth Opportunities Fund as well based on its networks the company has built with prestigious research and academic institutes, premier cluster organisations and hospitals.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!